News › Industry News, Patient Care

FBI Issues Safety Warning about Counterfeit Versions of Weight Loss Drug Semaglutide

March 19, 2025

The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide, the active ingredient in Ozempic and Wegovy, two prescription medications used for weight loss.

A notice on the FBI’s website warns that the fraudulent drugs purporting to contain semaglutide have been found instead to contain “compounded mixtures of unknown drugs that do not contain semaglutide, drugs with high levels of impurities, and unsafe or unapproved drugs.”

The health risks of taking the “misrepresented drugs” include everything from cardiac and gastrointestinal disorders to nervous system disorders, psychiatric disorders and death, according to the FBI.

Read more at Good Morning America >>

See the FBI-issued Public Service Announcement >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics